CytoSorbents’ Q3 2026 Financial Results Highlight Progress Towards Break-even Operations and Future Growth Opportunities

CytoSorbents Reports Solid Financial Progress in Q3 2026

CytoSorbents Corporation, listed on NASDAQ under the CTSA ticker, has recently unveiled its financial results for the third quarter that ended on September 30, 2026. The company has highlighted an encouraging trajectory with its operational cash flow hitting the breakeven point. This achievement is framed within a context of ongoing efforts to enhance business and regulatory infrastructures related to their blood purification technologies used for critical care and cardiac surgery.

Financial Highlights

In Q3 2026, CytoSorbents reported revenues reaching $9.7 million, marking a 3% increase compared to the previous year's third quarter revenue of $9.5 million. The growth can be credited largely to a 16% uptick in sales from distributors and strategic partners. Gross margins saw a significant improvement, rising to 75% from 73% in the previous quarter and 70% year-over-year. Interestingly, total operating expenses also saw a notable decrease of 11%, dropping from $9.5 million in Q3 2025 to $8.5 million in Q3 2026.

The company's operating loss improved remarkably, reducing by 59% to $1.2 million, compared to $2.9 million in the same period of 2025, while the net loss decreased by 42%, reaching $1.8 million or $0.58 per share. This aligns with a strategic objective to reduce cash burn and enhance financial health. The adjusted net loss, which factors out non-cash currency transactions and other expenses, also indicated considerable improvement, dropping to $1.5 million or $0.48 per share, compared to $2.6 million or $0.83 per share a year earlier.

Business Strategy & Future Outlook

Dr. Phillip Chan, CEO of CytoSorbents, acknowledged the third quarter as a pivotal time for the company, indicating that achieving breakeven operational cash flow signals strong financial discipline and effective management. He added that this success reflects improvements in cost structures and operational efficiency, positioning the company favorably for future growth.

CytoSorbents is focusing on four distinct value drivers that are expected to contribute significantly to shareholder value:

1. Sustainable Operating Cash Flow: The company successfully reached operating cash flow breakeven with a positive cash flow of approximately $43,000, excluding restructuring-related payments. This is pivotal for minimizing future financing needs.

2. Growth of Core Product CytoSorb: The management is aiming to restore profitability in the CytoSorb franchise. There was an 18% growth year-over-year in sales from distributors and strategic partners in Q3, although sales in Germany fell by 20%, which significantly affected overall growth. The company plans to enhance its sales force in Germany to invigorate this market.

3. U.S. Market Expansion via DrugSorb-ATR: Progress is being made towards obtaining FDA approval for DrugSorb-ATR, a technology designed to reduce bleeding complications during heart surgeries. CytoSorbents estimates a substantial addressable market for this product in the U.S. and Canada, potentially valued at $300 million to $2 billion.

4. Maximizing HemoDefend-BGA’s Potential: HemoDefend-BGA represents a unique blood purification technology aimed at simplifying blood product inventories, thus potentially improving hospital efficiencies. The company is exploring strategic partnerships to enhance the value of this technology, which has generated interest from various stakeholders.

Conclusion

Dr. Chan emphasized that with a disciplined approach to sustaining cash flow, increasing profitability in key products, and progressing toward regulatory approvals, CytoSorbents is well-positioned for the future. With significant operational improvements and multiple pathways for value creation, the company anticipates a favorable growth trajectory as it leverages its blood purification technologies to meet critical care needs globally.

The Q3 earnings call will include further discussions regarding these developments and anticipated strategies moving forward, as the company continues to forge its path in the medical technology landscape.